Tags

Type your tag names separated by a space and hit enter

Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study.
Br J Dermatol 2014; 170(1):150-6BJ

Abstract

BACKGROUND

There is only retrospective evidence for the efficacy of narrowband ultraviolet B (NB-UVB) in children with eczema.

OBJECTIVES

To measure the difference in means for objective scores [Six Area Six Sign Atopic Dermatitis score (SASSAD), percentage surface area] and quality-of-life scores, between patients treated with NB-UVB and unexposed cohorts at the end of treatment, and 3 and 6 months post-treatment.

METHODS

Twenty-nine children aged 3-16 years for whom NB-UVB was indicated, were scored prospectively using SASSAD and percentage surface area involvement at baseline, at 12 weeks (end of treatment) and 3 and 6 months post-NB-UVB. Their scores were compared with those of unexposed children (n = 26) for whom NB-UVB phototherapy was indicated and offered, but who chose not to undertake treatment.

RESULTS

There was a 61% reduction in mean SASSAD score in the NB-UVB cohort compared with an increase of 6% in the unexposed cohort. Mean SASSAD score for the NB-UVB cohort at the end of treatment was 11.6 vs. 24.8 for the unexposed; difference in means -13.2 [95% confidence interval (CI) -18.7 to -7.7, P < 0.0001]. Mean surface area involvement at the end of treatment was 11% for the NB-UVB cohort vs. 36% for the unexposed cohort; difference in means -25% (95% CI -34% to -16%, P < 0.0001). Subjective and quality-of-life scores showed significant difference between cohorts at the end of treatment (P < 0.05). Objective scores remained significantly lower than in the unexposed cohort 3 and 6 months after treatment.

CONCLUSION

NB-UVB is clinically effective and improves quality of life in children with moderate-to-severe eczema. The effect is maintained for 6 months after treatment.

Authors+Show Affiliations

Department of Dermatology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, U.K.No affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Evaluation Studies
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23937117

Citation

Darné, S, et al. "Narrowband Ultraviolet B Phototherapy in Children With Moderate-to-severe Eczema: a Comparative Cohort Study." The British Journal of Dermatology, vol. 170, no. 1, 2014, pp. 150-6.
Darné S, Leech SN, Taylor AE. Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study. Br J Dermatol. 2014;170(1):150-6.
Darné, S., Leech, S. N., & Taylor, A. E. (2014). Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study. The British Journal of Dermatology, 170(1), pp. 150-6. doi:10.1111/bjd.12580.
Darné S, Leech SN, Taylor AE. Narrowband Ultraviolet B Phototherapy in Children With Moderate-to-severe Eczema: a Comparative Cohort Study. Br J Dermatol. 2014;170(1):150-6. PubMed PMID: 23937117.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study. AU - Darné,S, AU - Leech,S N, AU - Taylor,A E M, PY - 2013/08/03/accepted PY - 2013/8/14/entrez PY - 2013/8/14/pubmed PY - 2015/1/15/medline SP - 150 EP - 6 JF - The British journal of dermatology JO - Br. J. Dermatol. VL - 170 IS - 1 N2 - BACKGROUND: There is only retrospective evidence for the efficacy of narrowband ultraviolet B (NB-UVB) in children with eczema. OBJECTIVES: To measure the difference in means for objective scores [Six Area Six Sign Atopic Dermatitis score (SASSAD), percentage surface area] and quality-of-life scores, between patients treated with NB-UVB and unexposed cohorts at the end of treatment, and 3 and 6 months post-treatment. METHODS: Twenty-nine children aged 3-16 years for whom NB-UVB was indicated, were scored prospectively using SASSAD and percentage surface area involvement at baseline, at 12 weeks (end of treatment) and 3 and 6 months post-NB-UVB. Their scores were compared with those of unexposed children (n = 26) for whom NB-UVB phototherapy was indicated and offered, but who chose not to undertake treatment. RESULTS: There was a 61% reduction in mean SASSAD score in the NB-UVB cohort compared with an increase of 6% in the unexposed cohort. Mean SASSAD score for the NB-UVB cohort at the end of treatment was 11.6 vs. 24.8 for the unexposed; difference in means -13.2 [95% confidence interval (CI) -18.7 to -7.7, P < 0.0001]. Mean surface area involvement at the end of treatment was 11% for the NB-UVB cohort vs. 36% for the unexposed cohort; difference in means -25% (95% CI -34% to -16%, P < 0.0001). Subjective and quality-of-life scores showed significant difference between cohorts at the end of treatment (P < 0.05). Objective scores remained significantly lower than in the unexposed cohort 3 and 6 months after treatment. CONCLUSION: NB-UVB is clinically effective and improves quality of life in children with moderate-to-severe eczema. The effect is maintained for 6 months after treatment. SN - 1365-2133 UR - https://www.unboundmedicine.com/medline/citation/23937117/full_citation L2 - https://doi.org/10.1111/bjd.12580 DB - PRIME DP - Unbound Medicine ER -